NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM).
Aftermarket on January 30, 2018, Bellicum issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States[.]” Therein, the Company announced that it had “received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.” BPX-501 is the Company’s lead clinical product candidate designed to improve outcomes for patients undergoing stem cell transplant who lack a matched donor.
On this news, the Company’s share price fell from $8.20 per share on January 30, 2018 to a closing price of $6.08 on January 31, 2018—a $2.12 or a 25.85% drop.
If you invested in Bellicum stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/BLCM. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
